Side Effect Guide
Constipation on CagriSema: Causes, Timeline & Management
Constipation is among the most commonly reported side effects in patients taking CagriSema. Understanding why it occurs, when it typically appears, and how to manage it effectively can significantly improve treatment experience.
⚠️ Medical Disclaimer
This page is for educational purposes only and does not constitute medical advice. GLP-1 medications are prescription drugs. Discuss all treatment decisions with a licensed healthcare provider who knows your complete medical history. Individual results vary significantly from clinical trial averages.
Prevalence
10–24% of patients report constipation
Onset
Usually first 2–8 weeks
Typically Resolves
Within 8–12 weeks at stable dose
Why Does CagriSema Cause Constipation?
GLP-1 receptor agonists slow gastric emptying and reduce intestinal motility, which decreases the frequency of bowel movements and can harden stool.
This effect is related to CagriSema's mechanism as a GLP-1 receptor agonist + Amylin analog (cagrilintide). The higher the dose, the more pronounced these receptor-mediated effects tend to be — which is why side effects often worsen with each dose escalation before improving.
How Common Is Constipation on CagriSema?
10–24% of patients report constipation, more common at higher doses. In the pivotal REDEFINE-1 trial, constipation was among the reported adverse events, consistent with the broader class effect. It was the most common reason for dose adjustment in some trial arms, though most participants chose to continue treatment.
Timeline: When Does It Start and Stop?
Can persist throughout treatment; often most notable in the first few months. Unlike nausea, constipation may not fully resolve.
A practical rule: if constipation appears after a dose escalation, give it 2–4 weeks before assuming it won't improve. Many patients who consider stopping for this reason find the symptom resolves on its own.
Management Strategies
Evidence-based approaches to managing constipation while continuing CagriSema treatment:
- ✓Increase daily water intake to ≥64 oz
- ✓Add dietary fiber (psyllium, fruits, vegetables)
- ✓Regular physical activity promotes motility
- ✓Stool softeners (docusate) or osmotic laxatives (MiraLAX) as needed
- ✓Avoid iron supplements which worsen constipation
If constipation is severe enough to prevent adequate nutrition or hydration, contact your prescriber. A temporary dose reduction or extended time at the current dose (8 weeks instead of 4) may be appropriate.
When to Call Your Doctor
- Inability to keep food or liquids down for more than 24 hours
- Signs of dehydration (extreme thirst, dark urine, dizziness)
- Severe abdominal pain (may indicate pancreatitis — seek immediate care)
- Constipation that has not improved after 6–8 weeks at a stable dose
- Any new or worsening symptoms that concern you
Specific Considerations for CagriSema
CagriSema combines semaglutide with the amylin analog cagrilintide achieving 22.7% mean weight loss in Phase 3 REDEFINE-1 — among the highest results seen for any non-surgical obesity treatment.
CagriSema is an investigational medication in Phase 3 clinical trials — not FDA-approved for clinical use. Its side effect profile has been characterized in REDEFINE-1 and related trials. Discuss any persistent or concerning symptoms with your prescriber.
📅 Dose Schedule Calculator
Track your titration schedule and know when to expect side effects to ease at each dose level.
View My Dose Schedule →